News

REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation without continuous administration of immune suppressants. “A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Costimulatory Blockade” was published in the AJT March 2014 Issue 3, Volume 14, [...]

Tokyo, Japan – February 14, 2014 – REGiMMUNE Corporation announced the closing of a Series D financing earlier this month. The company raised $9.2 million US in this new round, which was led by Japan Asia Investment Corporation (JAIC) and Nippon Venture Capital Corp (NVCC). Additional investors participating in this round are new investors Mizuho [...]

REGiMMUNE Completes $9.2 Million Series D Financing Tokyo, Japan – February 14, 2014 – REGiMMUNE Corporation announced the closing of a Series D financing earlier this month. The company raised $9.2 million US in this new round, which was led by Japan Asia Investment Corporation (JAIC) and Nippon Venture Capital Corp (NVCC). Additional investors participating [...]

Positive Phase I Clinical Trial Supports Initiation of Phase II Study in Patients with GvHD – Tokyo, Japan – February 6, 2014 – REGiMMUNE Corporation announced today that it has begun a Phase II study of its proprietary compound RGI-2001 for GvHD associated with hematopoietic stem cell transplantation. The multicenter study is being conducted in [...]

REGiMMUNE Begins Enrollment for Phase II Clinical Trial for Graft versus Host Disease – Positive Phase I Clinical Trial Supports Initiation of Phase II Study in Patients with GvHD – Tokyo, Japan – February 6, 2014 – REGiMMUNE Corporation announced today that it has begun a Phase II study of its proprietary compound RGI-2001 for [...]

REGiMMUNE Corporation relocated its US offices from Santa Clara to San Francisco, California. please see access page for the new address.

Tokyo, Japan., Dec 26, 2013  – REGiMMUNE Corporation (RGI) today announced that the Company has appointed Mr. Kenzo Kosuda to the position of senior vice president, chief financial officer (CFO), and a member of the board effective as of Today.  Mr. Kosuda has spent the over 20 years in various CFO positions for companies including Sparx [...]

Tokyo, Japan., Dec 26, 2013  – REGiMMUNE Corporation (RGI) today announced that the Company has appointed Mr. Kenzo Kosuda to the position of senior vice president, chief financial officer (CFO), and a member of the board effective as of Today.  Mr. Kosuda has spent the over 20 years in various CFO positions for companies including Sparx [...]

Santa Clara, CA and TOKYO — April 12, 2013 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has appointed Mr. Nakamura, Dr. Misawa, Dr. Matsuishi and Mr.Hirai the as non-executive director. Mr. Nakamura is currently the head at one of the venture investment sections and a member of the fund planning [...]

RGI-2001 has been granted Orphan Drug Designation for RGI-2001 from FDA Tokyo, Japan-(OCT. 28, 2012) – REGiMMUNE Corporation announced today that RGI-2001, the company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of Graft-versus-Host Disease (GvHD) associated with hematopoietic stem cell transplantation. [...]

Tokyo, Japan-(OCT. 28, 2012) – REGiMMUNE Corporation announced today that RGI-2001, the company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of Graft-versus-Host Disease (GvHD) associated with hematopoietic stem cell transplantation. Orphan Drug Designation is a special status granted by FDA to [...]

Second Tranche of Private Placement Announced REGiMMUNE announced the closing of the second tranche of a Preferred A financing. The company closed $0.5 million U.S. in the second tranche of previously announced financing (1/30/2012). In this tranche, Chibagin Capital (www.chibagincapital.co.jp) joined as an investor. Chibagin Capital is a VC arm of Chiba bank, which is the [...]

REGiMMUNE Corporation announced today that it has appointed Mr. Kohtaro Toda as a board member. He is currently an investment manager of Japan Asia Investment Co., Ltd. (JAIC), a Japanese venture capital firm with $1 billion under management. The addition of this new management position reflects the company’s continued progress into a clinical stage company, [...]

Tokyo, Japan – January 31, 2012 (US time)– REGiMMUNE Corporation said today that it has begun a Phase I/II study of its proprietary compound RGI-2001 for Graft versus Host Disease (GvHD) associated with hematopoietic stem cell transplantation. The safety and efficacy study will enroll approximately 50 bone marrow or peripheral blood stem cell transplantation leukemia [...]

Basis patent for the target specific tolerance induction by GalCer liposome, reVax technology, has been granted Tokyo, JAPAN–(Nov 28, 2011) – REGiMMUNE Corp. (“Company”) announces that the Japanese Patent Office has granted a patent, containing claims for a target specific tolerance induction technology, which we named reVax technology. The issued patent covers the GalCer liposome [...]